EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC-ND 4.0

Model-based dose selection and pharmacokinetic bridging of subcutaneous from intravenous pembrolizumab across indications

Gina Song, Mustafa Erman, Gastón Lucas Martinengo, Judit Kocsis, Gopal Kunta, Mengzhao Wang, Hiroshige Yoshioka, Carolina de Miranda Silva, Mallika Lala

European Journal of Cancer · 2025-11 · 230 · 115711

DOI: 10.1016/j.ejca.2025.115711 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift European Journal of Cancer, 2025-11. Verfasst von Gina Song und 8 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., Rahway, NJ, USA. Electronic address: gina.song@merck.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Models, Biological, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Merck Sharp and Dohme United Kingdom, MSD.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalModels, BiologicalNeoplasmsAdultAgedFemaleHumansMaleMiddle AgedAdministration, IntravenousBiological AvailabilityDose-Response Relationship, DrugInjections, SubcutaneousClinical Trials, Phase I as TopicClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

Anti–PD-1ImmunotherapyModelingPembrolizumabPharmacokinetic-based bridgingSubcutaneous administration

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalpembrolizumab

Autor:innen und Institutionen

  • Merck & Co., Inc., Rahway, NJ, USA. Electronic address: gina.song@merck.com.
  • Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Türkiye. Electronic address: ermanm1968@gmail.com.
  • Department of Clinical Oncology, Sanatorio Parque, Rosario, Argentina. Electronic address: gastonmartinengo74@hotmail.com.
  • Department of Oncoradiology, Bács-Kiskun Megyei Oktatókórház, Kecskemét, Hungary. Electronic address: kocsisjucidr@gmail.com.
  • Medical Oncology, Clermont Oncology Center, Clermont, FL, USA. Electronic address: drgkunta@aorcorp.com.
  • Department of Pulmonary Medicine, Peking Union Medical College Hospital, Beijing, People's Republic of China. Electronic address: mengzhaowang@sina.com.

Förderung

  • Merck Sharp and Dohme United Kingdom
  • MSD

Zitieren

APA

Song, G., Erman, M., Martinengo, G. L., Kocsis, J., Kunta, G., Wang, M., Yoshioka, H., de Miranda Silva, C., & Lala, M. (2025). Model-based dose selection and pharmacokinetic bridging of subcutaneous from intravenous pembrolizumab across indications. European Journal of Cancer, 230, 115711. https://doi.org/10.1016/j.ejca.2025.115711

Vancouver

Song G, Erman M, Martinengo GL, Kocsis J, Kunta G, Wang M, et al. Model-based dose selection and pharmacokinetic bridging of subcutaneous from intravenous pembrolizumab across indications. European Journal of Cancer. 2025;230:115711. doi:10.1016/j.ejca.2025.115711

BibTeX
@article{Song2025,
  author = {Song, Gina and Erman, Mustafa and Martinengo, Gastón Lucas and Kocsis, Judit and Kunta, Gopal and Wang, Mengzhao and Yoshioka, Hiroshige and de Miranda Silva, Carolina and Lala, Mallika},
  title = {Model-based dose selection and pharmacokinetic bridging of subcutaneous from intravenous pembrolizumab across indications},
  journal = {European Journal of Cancer},
  year = {2025},
  volume = {230},
  pages = {115711},
  doi = {10.1016/j.ejca.2025.115711}
}
Kostenlos starten →